Jaimin Patel, DO
Endocrinology, Diabetes & Metabolism · Charleston, SCNPI 1184923708
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 59 manufacturers, the largest accounting for just 19.6%.
Across 876 payments — averaging $41.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cequr Corporation$7K
- Mannkind Corporation$6K
- Amgen$5K
- Tandem Diabetes Care, Inc.$2K
- Abbott$2K
- Lilly USA, LLC$2K
- plus $12K from 53 others
What the payments were for
- Consulting fees$1,7005%
- Speaking & faculty fees$9,76027%
- Travel & lodging$5,47615%
- Food & beverage$19,57553%
- Education$1530%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$7,180
- AFREZZA$5,170
- TEPEZZA$3,400
- t:slim X2 Insulin Pump with Control-IQ$2,209
- EVENITY$467
- FARXIGA$345
- MINIMED 780G$313
- FREESTYLE LIBRE 3$308
- Omnipod$265
- Prolia$233
- Minimed 770G System$157
- NEXLIZET$122
- NEXLETOL$122
- FreeStyle Libre$121
- Tymlos$117
- TZIELD$115
- CRYSVITA$113
- Korlym$109
How this compares
$36,664 in reported general payments places this provider in the 85th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 219 | $332,768 |
| MounjaroTirzepatide | 162 | $297,768 |
| JardianceEmpagliflozin | 154 | $213,900 |
| TrulicityDulaglutide | 111 | $168,291 |
| RybelsusSemaglutide | 51 | $102,900 |
| Tresiba Flextouch U-100Insulin Degludec | 112 | $95,046 |
| FarxigaDapagliflozin Propanediol | 69 | $75,179 |
| JanuviaSitagliptin Phosphate | 54 | $65,388 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $64,025 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 48 | $58,082 |
| Humalog Kwikpen U-200Insulin Lispro | 17 | $40,635 |
| TymlosAbaloparatide | 13 | $34,671 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $31,690 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $19,442 |
| Cinacalcet Hcl | 37 | $18,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,857 | $469,958296 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $846 | $442,003290 claims |
| Boehringer IngelheimJardiance, Tradjenta | $713 | $231,602175 claims |
| MerckJanuvia, Janumet Xr | $79 | $77,70968 claims |
| AstraZenecaFarxiga | $1,290 | $75,17969 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $751 | $58,08248 claims |
| Radius Health, Inc.Tymlos | $354 | $34,67113 claims |
| Cequr CorporationCequr Simplicity | $7,197 | $13,80130 claims |
| AbbVieSynthroid | $301 | $9,06682 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $97 | $4,527420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Charleston
- Louis HaenelCharleston$377K
- Beatrice HullCharleston$214K
- Jyotika FernandesCharleston$12K
- Kathie HermayerCharleston$4K
- Eliana MilazzoCharleston$2K
- Gauri DhirMyrtle Beach$417K
- Cory WhiteGreenville$413K
- Vonda CalcuttWalterboro$368K
- Ray VaughtersAiken$321K
- Donald EagertonMyrtle Beach$284K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.